TY - JOUR
T1 - Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats
T2 - Relevance to a neurodevelopmental origin of schizophrenia?
AU - Guillemot, Johann
AU - Lukaszewski, Marie Amélie
AU - Montel, Valérie
AU - Delahaye, Fabien
AU - Mayeur, Sylvain
AU - Laborie, Christine
AU - Dickes-Coopman, Anne
AU - Dutriez-Casteloot, Isabelle
AU - Lesage, Jean
AU - Breton, Christophe
AU - Vieau, Didier
N1 - Funding Information:
Funding: This work was supported by Région Nord-Pas de Calais, France et le Fonds de Développement Européen Régional .
PY - 2011/9/30
Y1 - 2011/9/30
N2 - Epidemiological and experimental data indicate that maternal undernutrition may sensitize the offspring to the apparition of chronic diseases such as metabolic syndrome and schizophrenia, suggesting that these pathologies may have a developmental origin. To test this hypothesis, we have compared the effects of a 4 weeks treatment of clozapine (30 mg/kg once daily, p.o.) or aripiprazole (10 mg/kg once daily, p.o.) on metabolic and hormonal parameters in 4-month-old male animals from control or 70% prenatally food-restricted mothers (FR30 model). Both neuroleptics did not markedly modify body weight gain and food intake in both controls and FR30 rats. Clozapine decreased insulin secretion in both groups but significantly diminished leptin, corticosterone and glucose plasma levels only in FR30 animals. Aripiprazole decreased corticosterone plasma levels only in FR30 animals. Using quantitative RT-PCR array containing 84 obesity-related genes, we identified several genes involved in energy metabolism regulation whose expression was modified by clozapine or aripiprazole in adult male rat hypothalami. In addition, we demonstrated that expression of some of these genes was differentially affected by each neuroleptic in the hypothalamus of both FR30 and control animals. Although no marked metabolic alterations were observed in both control and FR30 animals after clozapine or aripiprazole treatment, our data indicate that offspring from undernourished mothers exhibit a modified sensitivity to atypical neuroleptics. Our results do not rule out a putative developmental origin of schizophrenia and may help to understand the way by which atypical neuroleptics, such as clozapine, sensitize schizophrenic patients to the development of metabolic disorders.
AB - Epidemiological and experimental data indicate that maternal undernutrition may sensitize the offspring to the apparition of chronic diseases such as metabolic syndrome and schizophrenia, suggesting that these pathologies may have a developmental origin. To test this hypothesis, we have compared the effects of a 4 weeks treatment of clozapine (30 mg/kg once daily, p.o.) or aripiprazole (10 mg/kg once daily, p.o.) on metabolic and hormonal parameters in 4-month-old male animals from control or 70% prenatally food-restricted mothers (FR30 model). Both neuroleptics did not markedly modify body weight gain and food intake in both controls and FR30 rats. Clozapine decreased insulin secretion in both groups but significantly diminished leptin, corticosterone and glucose plasma levels only in FR30 animals. Aripiprazole decreased corticosterone plasma levels only in FR30 animals. Using quantitative RT-PCR array containing 84 obesity-related genes, we identified several genes involved in energy metabolism regulation whose expression was modified by clozapine or aripiprazole in adult male rat hypothalami. In addition, we demonstrated that expression of some of these genes was differentially affected by each neuroleptic in the hypothalamus of both FR30 and control animals. Although no marked metabolic alterations were observed in both control and FR30 animals after clozapine or aripiprazole treatment, our data indicate that offspring from undernourished mothers exhibit a modified sensitivity to atypical neuroleptics. Our results do not rule out a putative developmental origin of schizophrenia and may help to understand the way by which atypical neuroleptics, such as clozapine, sensitize schizophrenic patients to the development of metabolic disorders.
KW - Atypical neuroleptics
KW - Hypothalamus
KW - Maternal undernutrition
KW - Metabolic syndrome
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=80051986237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051986237&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2011.04.011
DO - 10.1016/j.ejphar.2011.04.011
M3 - Article
C2 - 21514291
AN - SCOPUS:80051986237
SN - 0014-2999
VL - 667
SP - 402
EP - 409
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -